BSX Boston Scientific

Q2 2025 10-Q

Filed: Aug 1, 2025Period ending Jun 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Boston Scientific (BSX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 1, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• No specific quarterly revenue or YoY change figures provided in excerpt
• No profitability or margin % figures disclosed in excerpt

+3 more insights

Risk Factors

• No new or changed risk factors disclosed this quarter; risk section references most recent 10-K
• Carried-forward regulatory risk: ongoing compliance with Sarbanes-Oxley Act Sections 302 and 906 certifications by CEO and CFO

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$5.1B

Net Income

$797M

Gross Margin

67.6%

Operating Margin

16.2%

Net Margin

15.7%

Source: XBRL data from Boston Scientific Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Boston Scientific Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Boston Scientific

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.